Transgene provides an update on the Phase II study of the vaccine
The first results of the randomized Phase II trial evaluating the combination of TG4001 with avelumab versus avelumab alone in patients with HPV16-positive, recurrent or metastatic cervical and anogenital tumors show that the primary objective ( improvement in progression-free survival) was not achieved A subgroup analysis, planned in the protocol, showed a positive trend in … Read more